Relative Dose Intensity of Adjuvant Chemotherapy in Older Women With ER+ HER2- Breast Cancer.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06010615

Acronym

BREASTOLD

Enrollment

Registered

2023-08-24

Start date

2023-09-20

Completion date

2025-06-20

Last updated

2023-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Localized breast cancers are defined as high-risk when they include lymph node involvement, Ki67 \>30%, vascular emboli, low hormone receptor expression, or an unfavorable genomic signature result. Under these conditions, sequential adjuvant chemotherapy with taxanes and anthracyclines is recommended. Patients over 75 years of age receiving adjuvant chemotherapy are at greater risk of side-effects, which may necessitate dose reductions and a reduction in the intensity of chemotherapy. For curative adjuvant treatment, it is recommended to maintain a relative dose intensity (RDI) \> 85%. A few publications have demonstrated the prognostic impact of a relative dose intensity \< 85% for patients aged over 65. For several years now, the need for a specific assessment of elderly patients has been emphasized, prior to initiating oncological treatment (G8 score, onco-geriatric consultation). This study is a retrospective descriptive study of patients aged over 75 treated with adjuvant chemotherapy from 01/01/2012 to 01/01/2020 for RH+ HER2 - breast cancer in Franche Comté. Thus the investigators wish to identify patients at risk of receiving sub-optimal relative dose intensity, in order to guide early and targeted supportive care or geriatric co-management interventions.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

75 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women aged 75 or over * Patient with localized RH+HER2- breast cancer * Patient treated with adjuvant chemotherapy in Franche Comté between January 2012 and December 2019

Exclusion criteria

* Age \< 75 * Patient with metastatic breast cancer * Patient who received neoadjuvant chemotherapy * HER2+ breast cancer patient * Breast cancer patient with missing or negative hormonal status * Patient with localized recurrence of breast cancer with indication for new adjuvant therapy

Design outcomes

Primary

Measure	Time frame
Proportion of patients receiving relative dose intensity (RDI) <85%	01/01/2012 to 31/12/2019

Outcome results